Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Liabilities and Shareholders Equity (2020 - 2025)

Historic Liabilities and Shareholders Equity for Arcutis Biotherapeutics (ARQT) over the last 6 years, with Q3 2025 value amounting to $371.0 million.

  • Arcutis Biotherapeutics' Liabilities and Shareholders Equity fell 1517.7% to $371.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year decrease of 1678.1%. This contributed to the annual value of $348.9 million for FY2024, which is 220.41% up from last year.
  • Latest data reveals that Arcutis Biotherapeutics reported Liabilities and Shareholders Equity of $371.0 million as of Q3 2025, which was down 1517.7% from $352.4 million recorded in Q2 2025.
  • Arcutis Biotherapeutics' Liabilities and Shareholders Equity's 5-year high stood at $508.9 million during Q3 2022, with a 5-year trough of $293.0 million in Q3 2023.
  • For the 5-year period, Arcutis Biotherapeutics' Liabilities and Shareholders Equity averaged around $391.3 million, with its median value being $379.5 million (2023).
  • In the last 5 years, Arcutis Biotherapeutics' Liabilities and Shareholders Equity skyrocketed by 9544.58% in 2021 and then tumbled by 4243.45% in 2023.
  • Arcutis Biotherapeutics' Liabilities and Shareholders Equity (Quarter) stood at $408.2 million in 2021, then increased by 10.08% to $449.3 million in 2022, then dropped by 24.02% to $341.4 million in 2023, then rose by 2.2% to $348.9 million in 2024, then rose by 6.33% to $371.0 million in 2025.
  • Its last three reported values are $371.0 million in Q3 2025, $352.4 million for Q2 2025, and $344.1 million during Q1 2025.